Initial findings from the study indicate that by day 28, serum TTR levels in patients with ATTRv and polyneuropathy decreased by 52% (ranging from 47% to 56%) in the group that received a 0.1 mg per kilogram dose, while those receiving a 0.3 mg per kilogram dose showed an 87% reduction (ranging from 80% to 96%). Here, TTR is linked to polyneuropathy.